Victoria Parker
I am an experienced early clinical development (ECD) leader with a special focus on metabolic diseases. In this role, I am team lead for metabolism physicians and member of the early CVRM and ECD leadership teams. I am also responsible for defining and delivering the clinical research programmes for targets starting in the preclinical space all the way through to phase 2b, as well as supporting the overall clinical development programme to launch. My team and I work closely with a network of scientific advisory boards, global experts and study investigators to help inform the design, monitoring, and results interpretation of clinical studies.
I am a trained consultant in general internal medicine, endocrinology and pharmaceutical medicine. I also completed a PhD in clinical biochemistry and have a special interest in metabolism/endocrinology and rare diseases in this space. I joined AstraZeneca in 2016 and bring extensive early phase (First-In-Human to Ph2b) clinical trial experience and a strong track record in delivering high quality and robust study results. My therapy area expertise spans type 2 diabetes (T2D), chronic kidney disease (CKD), liver diseases, obesity and cardiovascular diseases.
I am deeply committed to building strong and diverse teams and enjoy my role as a mentor and coach for physicians and emerging talent in clinical research. For me, this is key to driving the science forward, through leveraging the talent and expertise of individuals with a shared passion for science and commitment to patient centricity.
It’s hugely rewarding to be at the forefront of developing new medicines for patients in one of the most exciting and innovative areas of clinical research, and to work with accomplished colleagues and clinical researchers globally.
CURRENT ROLE
2023-Present
2021-2023
2020
Featured publications
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Parker VER, Hoang T, Schlichthaar H, Gibb FW, Wenzel B, Posch MG, Rose L, Chang YT, Petrone M, Hansen L, Ambery P, Jermutus L, Heerspink HJL, McCrimmon RJ. Diabetes Obes Metab. 2022 Jul;24(7):1360-1369. doi: 10.1111/dom.14712. Epub 2022 Apr 25. PMID: 35403793; PMCID: PMC9323481.
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, Morice-Picard F, Petit F, Willems M, Bessis D, Jacquemont ML, Maruani A, Chiaverini C, Mirault T, Clayton-Smith J, Carpentier M, Fleck C, Maurer A, Yousfi M, Parker VER, Semple RK, Bardou M, Faivre L. Genet Med. 2021 Dec;23(12):2433-2442. doi: 10.1038/s41436-021-01290-y. Epub 2021 Aug 12. PMID: 34385668; PMCID: PMC8631579.
A standard of care for individuals with PIK3CA-related disorders: An international expert consensus statement.
A standard of care for individuals with PIK3CA-related disorders: An international expert consensus statement. Douzgou S, Rawson M, Baselga E, Danielpour M, Faivre L, Kashanian A, Keppler-Noreuil KM, Kuentz P, Mancini GMS, Maniere MC, Martinez-Glez V, Parker VE, Semple RK, Srivastava S, Vabres P, De Wit MY, Graham JM Jr, Clayton-Smith J, Mirzaa GM, Biesecker LG. Clin Genet. 2022 Jan;101(1):32-47. doi: 10.1111/cge.14027. Epub 2021 Jul 16. PMID: 34240408; PMCID: PMC8664971.
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz047. doi: 10.1210/clinem/dgz047. PMID: 31608926.
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, Darling TN, Gautier E, Goldspiel BR, Hadj-Rabia S, Harris J, Kounidas G, Kumar P, Lindhurst MJ, Loffroy R, Martin L, Phan A, Rother KI, Widemann BC, Wolters PL, Coubes C, Pinson L, Willems M, Vincent-Delorme C; PROMISE Working Group; Vabres P, Semple RK, Biesecker LG. Genet Med. 2019 May;21(5):1189-1198. doi: 10.1038/s41436-018-0297-9. Epub 2018 Oct 1. PMID: 30270358; PMCID: PMC6752269.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. PMID: 29945727.
The UK10K project: rare variants in health and disease. UK10K Consortium.
The UK10K project: rare variants in health and disease. UK10K Consortium; Walter K, Min JL, Huang J, Crooks L, Memari Y, McCarthy S, Perry JR, Xu C, Futema M, Lawson D, Iotchkova V, Schiffels S, Hendricks AE, Danecek P, Li R, Floyd J, Wain LV, Barroso I, Humphries SE, Hurles ME, Zeggini E, Barrett JC, Plagnol V, Richards JB, Greenwood CM, Timpson NJ, Durbin R, Soranzo N. Nature. 2015 Oct 1;526(7571):82-90. doi: 10.1038/nature14962. Epub 2015 Sep 14. PMID: 26367797; PMCID: PMC4773891.
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK. Nat Genet. 2012 Jun 24;44(8):928-33. doi: 10.1038/ng.2332. PMID: 22729222; PMCID: PMC3461408.
Veeva ID: Z4-59738
Date if preparation: November 2023